Sino Biopharm 1177

[winston]

not vested

SINO BIOPHARM Leaps 13%+ w/ Major Out-licensing Deal on Horizon

Lei Ming, who is responsible for handling capital markets at SINO BIOPHARM, stated that out-licensing has become one of the company's key strategic goals, and a heavyweight out-licensing deal is set to be finalized soon.

Related New: sCLSA: Biotech Stocks Largely Complete 1st Phase of Valuation Recovery; Liquidity & Fundamentals Expected to Improve

Starting this year, business development transactions will become a regular source of revenue and profit for SINO BIOPHARM, Lei revealed.

This will not only further increase the proportion of the company's international revenue to open up a second growth curve for its performance, but it may also serve as a catalyst for a revaluation of the company's worth.

Source: AAStocks Financial News

http://www.aastocks.com/en/stocks/analy ... stock-news

[winston]

not vested

SINO BIOPHARM (01177.HK) Plans to Launch 5 Innovative Products Annually Over Next 3 Yrs, Expects Landmark Out-Licensing Deal Soon

SINO BIOPHARM (01177.HK) announced that the proportion of revenue from the Group’s innovative products has risen from 16% in 2018 to 42% in 2024, with expectations to exceed 50% in 2025, marking a successful milestone in the Group’s innovation transformation.

Over the next three years, the Group plans to launch around five innovative products annually, aiming to further increase the proportion of revenue from innovative products to 60% by 2027.

This growth momentum is largely driven by the Group’s dual-engine strategy of “in-house R&D + business development (BD)”.

Related News: CLSA: Biotech Stocks Largely Complete 1st Phase of Valuation Recovery; Liquidity & Fundamentals Expected to Improve

The Group has announced 12 innovative products with breakthrough data (including four Late-Breaking Abstracts (LBA)) at the American Society of Clinical Oncology (ASCO) Annual Meeting, achieving a major breakthrough.

Since the beginning of this year, out-licensing has become one of the Group’s most critical strategic priorities, and an out-licensing deal is expected to be finalized soon.

Source: AAStocks Financial News

http://www.aastocks.com/en/stocks/analy ... stock-news

[winston]

<Research>BofAS Lifts SINO BIOPHARM's TP to HKD5.9, Reiterating Buy Rating

SINO BIOPHARM (01177.HK) has recently announced that a licensing deal is set to be finalized, and the company expects the proportion of innovative drug sales to rise above 50% this year and reach 60% by 2027 as driven by its "in-house R&D + external licensing" dual-engine strategy, according to a BofA Securities research report.

In addition, SINO BIOPHARM earlier received approval from China's National Medical Products Administration for its TQC3721 to enter Phase III clinical trials for the treatment of chronic obstructive pulmonary disease (COPD).

Related News: UOB Kay Hian: Industry Enters New Phase of Accelerated Growth; Top Picks INNOVENT BIO/ HANSOH PHARMA/ SINO BIOPHARM

BofA Securities raised its target price for SINO BIOPHARM from HKD5.1 to HKD5.9 and reiterated the Buy rating.

Source: AAStocks Financial News

http://www.aastocks.com/en/stocks/news/ ... -news/AAFN